Global Retirement Partners LLC Has $6.02 Million Stock Holdings in Cencora, Inc. (NYSE:COR)

by · The Cerbat Gem

Global Retirement Partners LLC raised its holdings in Cencora, Inc. (NYSE:COR – Free Report) by 5.1% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 26,741 shares of the company’s stock after acquiring an additional 1,290 shares during the quarter. Global Retirement Partners LLC’s holdings in Cencora were worth $6,019,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Good Life Advisors LLC lifted its stake in Cencora by 81.7% in the third quarter. Good Life Advisors LLC now owns 3,050 shares of the company’s stock valued at $687,000 after acquiring an additional 1,371 shares during the last quarter. nVerses Capital LLC lifted its stake in Cencora by 67.9% in the third quarter. nVerses Capital LLC now owns 4,700 shares of the company’s stock valued at $1,058,000 after acquiring an additional 1,900 shares during the last quarter. Hengehold Capital Management LLC acquired a new stake in Cencora in the third quarter valued at approximately $952,000. Seven Grand Managers LLC acquired a new stake in shares of Cencora in the third quarter worth $16,881,000. Finally, Vontobel Holding Ltd. lifted its stake in shares of Cencora by 1.4% in the third quarter. Vontobel Holding Ltd. now owns 4,250 shares of the company’s stock worth $957,000 after buying an additional 58 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,473 shares of the business’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total value of $357,482.37. Following the sale, the executive vice president now owns 10,948 shares of the company’s stock, valued at $2,656,970.12. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, EVP Silvana Battaglia sold 1,473 shares of the business’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total value of $357,482.37. Following the sale, the executive vice president now owns 10,948 shares in the company, valued at approximately $2,656,970.12. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the business’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $240.56, for a total transaction of $1,067,646,415.76. Following the completion of the sale, the insider now owns 19,980,000 shares in the company, valued at $4,806,388,800. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 15.80% of the company’s stock.

Cencora Stock Performance

COR stock traded down $0.98 on Thursday, reaching $235.59. 383,757 shares of the company were exchanged, compared to its average volume of 1,420,593. Cencora, Inc. has a 12 month low of $182.75 and a 12 month high of $247.66. The stock’s fifty day moving average price is $232.42 and its 200 day moving average price is $231.15. The firm has a market capitalization of $46.99 billion, a PE ratio of 25.89, a PEG ratio of 1.40 and a beta of 0.44. The company has a debt-to-equity ratio of 3.93, a current ratio of 0.89 and a quick ratio of 0.55.

Cencora (NYSE:COR – Get Free Report) last announced its earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.18 by $0.16. The business had revenue of $74.20 billion for the quarter, compared to analyst estimates of $73.32 billion. Cencora had a net margin of 0.65% and a return on equity of 266.60%. Cencora’s revenue was up 10.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.92 earnings per share. On average, research analysts anticipate that Cencora, Inc. will post 13.63 EPS for the current fiscal year.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, August 26th. Shareholders of record on Friday, August 9th were issued a $0.51 dividend. This represents a $2.04 annualized dividend and a yield of 0.87%. The ex-dividend date was Friday, August 9th. Cencora’s dividend payout ratio (DPR) is presently 22.32%.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 21st. Evercore ISI reduced their price objective on shares of Cencora from $270.00 to $250.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Bank of America restated a “neutral” rating and issued a $245.00 price objective (down from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Leerink Partners reduced their price objective on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a research note on Monday, October 7th. Finally, Robert W. Baird reduced their price objective on shares of Cencora from $287.00 to $283.00 and set an “outperform” rating for the company in a research note on Friday, September 6th. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $259.44.

Check Out Our Latest Report on Cencora

About Cencora

(Free Report)

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

Recommended Stories